Emerging Players In Contraceptives Could Reshape A Mature Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The highly competitive, extensively generic contraceptive market has long been characterized by incremental changes in hormone dose, delivery and regimen. But Actavis’ emergence over the past year as a new powerhouse in women’s health is setting the stage for the first new estrogen component in years.